Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8463336 | 0.83 | RIPK1 (0.32) | RIPK1 | |
| SCHEMBL18893563 | 0.80 | CYP1A2 (0.39) | CYP1A2 | |
| SCHEMBL5138301 | 0.79 | CYP1A2 (0.43) | CYP1A2 | |
| SCHEMBL13829178 | 0.79 | TSHR (0.31) | RIPK1 | |
| SCHEMBL11457365 | 0.79 | RIPK1 (0.30) | RIPK1 | |
| SCHEMBL12060203 | 0.79 | TSHR (0.31) | RIPK1 | |
| SCHEMBL17482399 | 0.79 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL14341529 | 0.78 | TSHR (0.33) | RIPK1 | |
| SCHEMBL8463086 | 0.78 | MMP8 (0.31) | CYP1A2 | |
| SCHEMBL11430316 | 0.78 | TSHR (0.31) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348388-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | AMICUS THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11685718-B2 | Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds | AMICUS THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022119792-A1 | PRODUCTION OF 2,2,4,4-TETRAMETHYLCYCLOBUTANE-1, 3-DIOL FROM ISOBUTANOL USING A HOMOGENEOUS CATALYST | EASTMAN CHEMICAL COMPANY (US) | 2022-06-09 | — | — | WO | disclosed |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-01 | — | — | US | disclosed |
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-11-23 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| EP-1497373-B1 | THERMOSET COMPOSITION, METHOD, AND ARTICLE | GEN ELECTRIC (US) | 2007-02-07 | — | — | EP | disclosed |
| US-4306047-A | Propylene polymerization | SHELL OIL COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| US-4269732-A | Olefin polymerization catalysts | SHELL OIL COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | CYP1A2 1856/4885RIPK1 1681/4885 |
| US-20170334815-A1 | CATALYST AND METHOD FOR HYDROGENATION OF 1,3-CYCLOBUTANEDIKETONE COMPOUND | CXXC5, ZRANB2, GZMB | CYP1A2 1940/4885RIPK1 3889/4885 |
| US-20230348388-A1 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | GANAB, GALK1, GANC | CYP1A2 2076/4885RIPK1 2187/4885 |
| US-20180057505-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, PARP12, TFPI2 | CYP1A2 594/4885RIPK1 351/4885 |
| US-20200407371-A1 | SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF | BAZ2A, BRD3, BRPF3 | CYP1A2 4582/4885RIPK1 211/4885 |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | CYP1A2 104/4885RIPK1 1230/4885 |
| US-11685718-B2 | Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds | GALK1, GANAB, MGAM | CYP1A2 1699/4885RIPK1 2378/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | CYP1A2 4582/4885RIPK1 211/4885 |
| US-20230330254-A1 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | GLP1R, GIPR, GCGR | CYP1A2 4174/4885RIPK1 2507/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | CYP1A2 278/4885RIPK1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.